Friday, May 26, 2006

Genentech seeks OK on Avastin for breast cancer

Drug development company Genentech Inc. on Thursday said it filed for regulatory approval to treat breast cancer using its Avastin monoclonal antibody in conjunction with standard chemotherapy.Genentech filed with the Food and Drug Administration for priority review of a supplemental Biologics License Application based on data from a late-stage trial that showed standard chemotherapy used with Avastin delivered a 52 percent reduction in the risk of disease progression or death compared with patients who only got the chemotherapy.The study was conducted on 722 patients with previously untreated, locally recurrent or metastatic breast cancer. Avastin inhibits a protein that promotes tumor growth and is already approved to treat colorectal cancer in conjunction with a form of intravenous chemotherapy. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */